Magnasense Investor Relations Material
Latest events
Q2 2025
29 Aug, 2025
Q4 2024
5 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Magnasense
Access all reports
Magnasense, a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. Magnasense's main product is the Oncolynx®, a urine test to be used with treatment of colorectal cancer patients. The test measures the levels of the drug in the bloodstream. This helps physicians optimize the dosage to achieve effective and safe treatment of cancer with biological drugs. The company was incorporated in 2019 and is based in Lund, Sweden.
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
MAGNA
Country
🇸🇪 Sweden